Vara is the first AI system CE-certified for autonomous triage in breast screening, where clearly-normal examinations are read by the AI system without a radiologist.
Public source
Publisher name
Public post
We’re happy to announce that Vara is the first AI system CE-certified for autonomous triage in breast screening, where clearly-normal examinations are read by the AI sys…
Company
Vara
- Industry
- Hospitals and Health Care
- Location
- Berlin, DE
- Company size
- 51–200 employees
About Vara
Better breast cancer screening should be a universal offering to every woman in the world. Vara’s AI-powered software platform, created with screening radiologists in Germany, mitigates much of the human subjectivity associated with reading mammography results—and reduces the repetitive work screening physicians are routinely subjected to—we’re making breast cancer screening more effective, more measurable, and more accessible for everyone, everywhere. By democratising access to early screening around the world, we deliver measurable impact backed by clinical evidence. We are partnering globally, to deliver breast cancer screening where it is needed most.
See moreLatest activity
Latest activity from Vara
4 signals
Legal & Regulatory
Vara received CE certification under EU MDR Class IIb for its autonomous triage system allowing normal screening mammograms to be reported without radiologist review.
Research & Knowledge
Vara published the PRAIM study as the only nationwide and still largest prospective study in the world in 2025.
Presence & Recognition
Vara's colleague Carla Gerlach represented Vara at the Merantix AI Campus to discuss German AI and reimbursement requirements.
Discover more
Similar signals
Similar public activity from other companies.
Legal & Regulatory
Skin Analytics
Skin Analytics secured a Class III CE mark for DERM, allowing DERM to autonomously discharge benign skin cancer cases from its clinical pathways.
Legal & Regulatory
Radiological Society of North America (RSNA)
Radiological Society of North America (RSNA) announced that a breast AI tool has received CE certification under the EU Medical Device Regulation (Class IIb) for autonomous triage in organized breast cancer screening, allowing it to report screening examinations as normal without a second confirmatory review from a radiologist.
Legal & Regulatory
Joint Commission
Joint Commission offers the Responsible Use of AI in Health Care Certification program to guide the responsible implementation of AI while keeping quality care and patient safety in focus.
Legal & Regulatory
CareAlly AI
CareAlly AI reported that CMS enforcement actions stopped more than $1.6 billion in potentially improper Medicare laboratory payments, attributed to advanced analytics, including AI and machine learning.
Legal & Regulatory
Infermedica